我们非常重视您的个人隐私,当您访问我们的网站时,请同意使用的所有cookie。有关个人数据处理的更多信息可访问《隐私条款》

    • asco2025.png
      05/28/2025

      ASCO 2025 Oral Presentation

      Efficacy and safety of cafelkibart (LM-108), an anti-CCR8 monoclonal antibody, in combination with anti-PD-1 therapy in patients with pancreatic cancer: Results from phase 1/2 studies


    • asco-annual-meeting-2024_big.jpeg
      05/29/2024

      ASCO 2024 Oral Presentation

      Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: Results from phase 1/2 studies

    • pic-245.jpg
      2022-08-23

      AACR 2022

      Effective Depletion of Tumor-infiltrating Tregs by a Novel Anti-CCR8 Antibody (LM-108): Addressing Resistance Associated with Immune Checkpoint Inhibitors, Jie Luo, Wentao Huang, Junwei Yang, Jin Li, Yifan Li, Da Fei, Xia Qin, Runsheng Li